The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate Cancer

An emerging challenge in prostate cancer (PCa) treatment is the development of drug cross-resistance, wherein resistance to enzalutamide (ENZ), an androgen receptor signaling inhibitor (ARSI), also confers resistance to subsequent ARSI and docetaxel (DTX) treatments. The mechanisms underlying this d...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Pedro T. Ochoa, Evelyn S. Sanchez-Hernandez, Alfonso M. Duran, Kai Wen Cheng, Joel Philip, Tise Suzuki, Julia J. Unternaehrer, Julie Dutil, Bhaskar Das, Rituparna Ganguly, Yasmine Baca, David de Semir, Charles Wang, Isaac Kremsky, Carlos A. Casiano
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2025-10-01
Σειρά:	Cells
Θέματα:	docetaxel drug cross-resistance enzalutamide glucocorticoid receptor HSP27 LEDGF/p75
Διαθέσιμο Online:	https://www.mdpi.com/2073-4409/14/19/1566
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!